Expression of nestin, cd133 and sox2 in meningiomas

Xiao, Zongyu; Chen, Xiaojuan; Pan, Qi; Yang, Qingzhi; Li, Kun-Zheng

doi:10.5137/1019-5149.jtn.21234-17.2

Cited by 3 publications

(4 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in non-muscle-invasive bladder cancer, lower expression of BRINP1 is associated with unfavorable prognosis [69]. PROM1 is a pentaspan transmembrane glycoprotein that has been described by different research groups as a CSC factor in meningiomas [9, 10, 12, 13]. In our survey, PROM1 was markedly downregulated in DCC low expression meningiomas in five array expression studies.…”

Section: Discussionmentioning

confidence: 64%

“…The involvement of CSCs in different types of cancer is seemingly complex. Thus far, only a limited number of CSC genes and mechanisms have been identified and characterized in meningiomas [9–13]. Meningioma stromal mesenchymal stem-like cells, similar to bone marrow mesenchymal stem cells (SC), have been detected in meningiomas [3].…”

Section: Introductionmentioning

confidence: 99%

“…A recent immunohistochemical survey in GI meningiomas identified a number of SC markers, including OCT4, NANOG, SOX2, KLF4, and c-MYC, on microvessels that led to the suggestion that these vessels may be associated with meningioma initiation [14]. An immunohistochemical study detected higher expression of nestin (NES), SOX2, and prominin 1 (PROM1), also known as CD133, in more progressive meningiomas [9]. In meningioma cultures, cells with pleomorphic characteristics show markedly increased numbers of CSCs scoring positive for PROM1 and SOX2, or AGR2 and BMI1 [12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas

Schulten

Hussein

2019

PLoS ONE

View full text Add to dashboard Cite

Background Meningiomas are the most common intracranial tumors, with a subset of cases bearing a progressive phenotype. The DCC netrin 1 receptor ( DCC ) is a candidate gene for early meningioma progression. Cancer stem cell (CSC) genes are emerging as cancer therapeutic targets, as their expression is frequently associated with aggressive tumor phenotypes. The main objective of the study was to identify deregulated CSC genes in meningiomas. Materials and methods Interrogating two expression data repositories, significantly differentially expressed genes (DEGs) were determined using DCC low vs . DCC high expression groups and WHO grade I (GI) vs . grade II + grade III (GII + GIII) comparison groups. Human stem cell (SC) genes were compiled from two published data sets and were extracted from the DEG lists. Biofunctional analysis was performed to assess associations between genes or molecules. Results In the DCC low vs . DCC high expression groups, we assessed seven studies representing each between seven and 58 samples. The type I transmembrane protein podocalyxin like ( PODXL ) was markedly upregulated in DCC low expression meningiomas in six studies. Other CSC genes repeatedly deregulated included, e . g ., BMP/retinoic acid inducible neural specific 1 ( BRINP1 ), prominin 1 ( PROM1 ), solute carrier family 24 member 3 ( SLC24A3 ), rRho GTPase activating protein 28 ( ARHGAP28 ), Kruppel like factor 5 ( KLF5 ), and leucine rich repeat containing G protein-coupled receptor 4 ( LGR4 ). In the GI vs . GII + GIII comparison groups, we assessed six studies representing each between nine and 68 samples. DNA topoisomerase 2-alpha ( TOP2A ) was markedly upregulated in GII + GIII meningiomas in four studies. Other CSC genes repeatedly deregulated included, e . g ., ARHGAP28 and PODXL . Network analysis revealed associations of molecules with, e . g ., cellular development and movement; nervous system development and function; and cancer. Conclusions This meta-analysis on meningiomas identified a comprehensive list of deregulated CSC genes across different array expression studies. Especially, PODXL is of interest for functional assessment in progressive meningiomas.

show abstract

Section: Discussionmentioning

confidence: 64%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas

Schulten

Hussein

2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Characteristic features of tumor stem-like cells include spherical formation, self-renewal to secondary neurospheres or subspheres, and expression of stem-like markers of their corresponding parental tumors. 55 In our study, we have considered the expression of CD133, CD44, Nestin, VIM, and SOX2 as indicative of stemness markers, 56 − 59 IDH1 as a diagnostic marker of gliomas, 8 GFAP as an astrocytic marker; 60 and βIII-tubulin as a representative of neuronal differentiated cells. 61 Our developed spheroids have shown enhanced self-renewal with expression of stemness gene markers of VIM, Nestin, CD44, GFAP, IDH1, and βIII-tubulin, which were confirmed by proteomic analysis.…”

Section: Discussionmentioning

confidence: 99%

Differential Proteome Profiling Analysis under Pesticide Stress by the Use of a Nano-UHPLC-MS/MS Untargeted Proteomic-Based Approach on a 3D-Developed Neurospheroid Model: Identification of Protein Interactions, Prognostic Biomarkers, and Potential Therapeutic Targets in Human IDH Mutant High-Grade Gliomas

Louati,

Maalej,

Kolsi

et al. 2023

J. Proteome Res.

View full text Add to dashboard Cite

High-grade gliomas represent the most common group of infiltrative primary brain tumors in adults associated with high invasiveness, agressivity, and resistance to therapy, which highlights the need to develop potent drugs with novel mechanisms of action. The aim of this study is to reveal changes in proteome profiles under stressful conditions to identify prognostic biomarkers and altered apoptogenic pathways involved in the anticancer action of human isocitrate dehydrogenase (IDH) mutant high-grade gliomas. Our protocol consists first of a 3D in vitro developing neurospheroid model and then treatment by a pesticide mixture at relevant concentrations. Furthermore, we adopted an untargeted proteomic-based approach with high-resolution mass spectrometry for a comparative analysis of the differentially expressed proteins between treated and nontreated spheroids. Our analysis revealed that the majority of altered proteins were key members in glioma pathogenesis, implicated in the cellular metabolism, biological regulation, binding, and catalytic and structural activity and linked to many cascading regulatory pathways. Our finding revealed that grade-IV astrocytomas promote the downstream of the mitogen-activated-protein-kinases/extracellular-signal-regulated kinase (MAPK1/ERK2) pathway involving massive calcium influx. The gonadotrophin-releasing-hormone signaling enhances MAKP activity and may serve as a negative feedback compensating regulator. Thus, our study can pave the way for effective new therapeutic and diagnostic strategies to improve the overall survival.

show abstract

Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature

Peng

Yuan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Meningiomas, the most frequent primary intracranial tumors of the central nervous system in adults, originate from the meninges and meningeal spaces. Surgical resection and adjuvant radiation are considered the preferred treatment options. Although most meningiomas are benign and slow-growing, some patients suffer from tumor recurrence and disease progression, eventually resulting in poorer clinical outcomes, including malignant transformation and death. It is thus crucial to identify these “high-risk” tumors early; this requires an in-depth understanding of the molecular and genetic alterations, thereby providing a theoretical foundation for establishing personalized and precise treatment in the future. Here, we review the most up-to-date knowledge of the cellular biological alterations involved in the progression of meningiomas, including cell proliferation, neo-angiogenesis, inhibition of apoptosis, and immunogenicity. Focused genetic alterations, including chromosomal abnormalities and DNA methylation patterns, are summarized and discussed in detail. We also present latest therapeutic targets and clinical trials for meningiomas' treatment. A further understanding of cellular biological and genetic alterations will provide new prospects for the accurate screening and treatment of recurrent and progressive meningiomas.

show abstract

Expression of nestin, cd133 and sox2 in meningiomas

Abstract: Nestin, CD133 and Sox2 expression levels may be correlated with the WHO pathological grade. Specifically, more aggressive meningiomas are characterized by higher positivity rates and higher levels of Nestin, CD133 and Sox2 expression in positive cells.

Cited by 3 publications

References 25 publications

Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas

Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas

Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature

Contact Info

Product

Resources

About